Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company operating in the precision oncology industry. The company focuses on discovering and developing targeted cancer therapies that are guided by predictive biomarkers designed to identify patients most likely to respond to treatment. Its core strategy integrates drug development with a proprietary functional precision medicine platform intended to improve clinical success rates in oncology.
The company’s primary value driver is its lead oncology pipeline, anchored by a differentiated biomarker-driven development approach. Acrivon’s lead product candidate, ACR-368 (a WEE1 pathway inhibitor), is being developed for select solid tumors with defined molecular characteristics. The company was founded in 2018 and became publicly traded in 2022 following its initial public offering, evolving from a privately funded biotech into a Nasdaq-listed precision oncology company.
Business Operations
Acrivon operates as a single-reportable-segment biotechnology company focused on the research and clinical development of oncology therapeutics. Its operations center on the discovery, clinical validation, and regulatory advancement of drug candidates using its proprietary AP3 Precision Proteomics Platform, which is designed to generate functional, proteomics-based predictive biomarkers.
The company conducts clinical trials primarily through outsourced clinical research organizations and maintains internal capabilities in translational science, biomarker development, and regulatory strategy. Acrivon does not manufacture products for commercial sale and currently generates no product revenue, relying instead on equity financing to fund operations. As of publicly available disclosures, the company does not report material revenue from partnerships, and data on material joint ventures is inconclusive based on available public sources.
Strategic Position & Investments
Acrivon’s strategic direction emphasizes biomarker-defined oncology drug development, aiming to pair targeted therapies with validated patient selection strategies. The company’s growth initiatives focus on advancing ACR-368 through mid-stage clinical trials and expanding the application of its AP3 Precision Proteomics Platform across additional tumor types and future pipeline candidates.
The company acquired rights to its lead compound from Eli Lilly and Company, re-developing the asset with a precision medicine framework that differentiates it from prior clinical efforts. Beyond its lead program, Acrivon has disclosed early-stage discovery efforts, though details on additional named pipeline assets remain limited in public filings. No material acquisitions or equity investments in external portfolio companies have been publicly confirmed beyond licensed assets.
Geographic Footprint
Acrivon Therapeutics is headquartered in Watertown, Massachusetts, within the United States, and operates primarily in North America. Its executive leadership, research operations, and corporate functions are based in this region.
Clinical development activities extend internationally through trial sites in Europe and other global regions, depending on study design and regulatory requirements. While the company has an international clinical footprint, it does not currently maintain significant physical operations or regional offices outside the United States based on available public disclosures.
Leadership & Governance
Acrivon is led by an executive team with experience in oncology drug development, translational science, and biopharmaceutical operations. The company emphasizes a leadership philosophy centered on data-driven decision-making and biomarker-led clinical development to improve patient outcomes and capital efficiency.
Key executives include:
- Peter Hoecklin, Ph.D. – President & Chief Executive Officer
- Tomasz Beer, M.D. – Chief Medical Officer (data inconclusive based on available public sources)
- Jonathan Lim – Chief Financial Officer (data inconclusive based on available public sources)
The board and management team collectively bring experience from large pharmaceutical companies and emerging biotech firms, with governance practices aligned to U.S. public company standards.